Berenberg raises target for Evonik stock to EUR 20.00

Published on 10/05/2026 at 13:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Berenberg shifts Evonik from Sell to Hold on October 5, 2026. Evonik stock costs EUR 20.92 versus EUR 20.65, plus 1.31 percent.

Aquarellmalerei der Essener Skyline mit Villa Hügel und Industriesilhouetten am Baldeneysee — Evonik Industries DE000EVNK013 als Aquarellmalerei der Essener Stadtlandschaft mit Industriesilhouette am Baldeneysee, Illustration mit AI erstellt.

Evonik Industries AG (ISIN DE000EVNK013) was trading at EUR 20.92 at Lang & Schwarz on October 5, 2026, as Berenberg raised its price target from EUR 15.50 to EUR 20.00 and upgraded the rating from Sell to Hold. The analyst action, reported by Investing.com on October 5, 2026, ties the change to BASF interest in a possible takeover.

Takeover approach resets the valuation debate

EQS News reported on September 25, 2026, that Evonik confirmed receiving a non-binding approach from BASF for a voluntary public takeover offer covering all shares. Evonik also stated in that release that talks were not taking place at that time, so the valuation argument rests on optionality rather than a signed transaction.

The contrast is important for the stock. Berenberg now sees the takeover interest as a potential floor even if methionine prices weaken, while its earlier Sell view reflected expected earnings pressure from commoditization in methionine and other portfolio areas.

Second-quarter EBITDA climbed 24 percent

Evonik entered the debate with a strong second quarter. The Yahoo Finance transcript states that adjusted EBITDA rose 24 percent year over year to EUR 630.00 million in the second quarter of 2026, with higher volumes and prices each contributing 7 percent. Adjusted EBITDA reached EUR 1.10 billion in the first half of 2026, according to the same transcript.

Management also said the third quarter was not showing a slowdown at the time of the August 4, 2026, call, while cautioning that normalization could affect the fourth quarter. That tension leaves the next report as a direct test of whether the temporary earnings boost is broadening beyond methionine.

November 3 is the next results checkpoint

Evonik's investor-relations calendar lists November 3, 2026, for reporting on the third quarter of 2026. The company has also identified specialty chemicals as its core business, while the upcoming report will help investors compare the takeover narrative with operating performance.

Stock trades 0.57 percent below yearly high

At Lang & Schwarz, Evonik stock was trading at EUR 20.92 on October 5, 2026, at 1:42 p.m. CEST, up 1.31 percent versus the prior close of EUR 20.65. The EUR 21.04 52-week high was 0.57 percent above the price, while market capitalization stood at EUR 9.7 billion on the same date. The further course of trading is shown by the continuously updated real-time quote of Evonik stock.